National Resilience acquired the Triangle office in 2021. Since then, funding for gene therapy solutions has fallen.

VIVEbiotech is also collaborating with a range of different suppliers to make its operations as efficient as possible.

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...

XyloCor Therapeutics Inc., a Wayne gene therapy company, received $67.5 million from investors to support Phase 2 trials of a treatment designed to grow new blood vessels in the heart, XyloCor ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

UC San Diego Health one of a few health care systems on West Coast to offer new gene therapy for hemophilia B.

Gil Blum, an analyst from Needham, maintained the Buy rating on Taysha Gene Therapies (TSHA – Research Report). The associated price target ...

A new study published in the peer-reviewed journal Human Gene Therapy involved the generation of a human monoclonal antibody ...